Molecular Partners
Swiss clinical-stage biopharmaceutical company developing DARPin-based medicines.
Last updated August 26, 2026
AI crawler reads
No AI crawler has read this profile since Oct 28, 2026.
Overview
Molecular Partners AG is a Swiss clinical-stage biopharmaceutical company headquartered in Zürich. It develops medicines based on DARPins, or Designed Ankyrin Repeat Proteins, a class of genetically engineered small-protein binding molecules intended to provide an alternative to conventional antibody-based therapeutics. The company was established in 2004 by researchers associated with the University of Zürich who were studying antibody technologies and developed the DARPin platform as the basis for a new biotechnology business. DARPins are derived from naturally occurring ankyrin repeat proteins. They can be engineered to bind selected biological targets with high affinity and specificity. A basic DARPin may contain a single binding domain, while several domains can be linked to create multi-DARPin molecules capable of engaging more than one target or combining different biological functions. Their comparatively small size and modular structure are central to Molecular Partners' development strategy. The company has presented the platform as suitable for designing potent, specific and versatile therapeutic proteins, as well as research and diagnostic tools. Molecular Partners has applied the DARPin technology across several therapeutic areas, including oncology, immuno-oncology, ophthalmology and infectious diseases. Its development model combines internal research with licensing, collaboration and co-development arrangements involving larger pharmaceutical companies. The company entered into a series of ophthalmology agreements with Allergan in 2011 and 2012, including the licensing of the ophthalmic candidate abicipar and later agreements covering the discovery, development and commercialization of additional DARPin products. It has also licensed or partnered selected candidates with companies including Amgen, Roche and Janssen, according to company and reference descriptions. The company became publicly traded on the SIX Swiss Exchange in November 2014 under the ticker MOLN. In July 2021, it added a Nasdaq listing in the United States under the same ticker. Its public-market profile has supported the financing of a research-intensive business whose value depends on advancing candidates through preclinical and clinical development, establishing partnerships and potentially achieving regulatory approval. In October 2020, Novartis acquired a six-percent stake in Molecular Partners at CHF 23 per share as part of a collaboration focused on developing therapeutic drugs against COVID-19. The transaction illustrated the company's use of strategic partnerships and external capital to pursue new applications for the DARPin platform. Molecular Partners remains a biotechnology company rather than a diversified pharmaceutical manufacturer: its principal activities are discovery research, clinical development, platform licensing and collaboration. Its pipeline has included two DARPin molecules in clinical development at the time described by the reference material, alongside a broader group of preclinical programs. The company therefore occupies a specialist position in the biopharmaceutical sector, centered on engineered protein therapeutics and partnerships intended to translate the DARPin platform into medicines for serious diseases.
History
Molecular Partners originated in research conducted at the University of Zürich. In 2004, researchers studying monoclonal antibodies formed Molecular Partners AG to commercialize a different class of engineered binding proteins known as DARPins. The platform was based on ankyrin repeat proteins, naturally occurring structural motifs involved in functions such as cellular signaling and receptor binding. By engineering these repeats, the researchers sought to create compact proteins that could be designed to recognize selected molecular targets with high affinity and specificity. The DARPin concept became the foundation of the company's research and business model. Unlike a conventional antibody, which generally uses a larger immunoglobulin structure to bind a target, a DARPin can be built from one or more engineered repeat domains. Mono-DARPins contain one target-binding domain and typically have a molecular mass of approximately 15 to 20 kilodaltons, while linked multi-DARPins can combine several binding activities within one molecule. This modularity has allowed Molecular Partners to investigate applications in which simultaneous engagement of multiple targets may be useful, particularly in cancer, immuno-oncology, ophthalmology and infectious diseases. The company initially developed its own pipeline while also pursuing licensing and collaboration agreements with larger pharmaceutical businesses. Its ophthalmology strategy led to a major relationship with Allergan. In 2011, Molecular Partners licensed its then-leading ophthalmic candidate, abicipar, to Allergan. The relationship expanded in 2012 through two additional agreements relating to the discovery, development and commercialization of proprietary DARPin products for serious eye diseases. The company also licensed or partnered other DARPin candidates with international pharmaceutical companies including Amgen, Roche and Janssen. These arrangements provided routes to external development expertise and potential commercialization while allowing Molecular Partners to concentrate on platform research and candidate generation. Molecular Partners entered the public markets in November 2014, when its shares were listed on the SIX Swiss Exchange under the ticker MOLN. The listing marked a transition from a privately financed research enterprise to a publicly accountable clinical-stage biotechnology company. It later broadened its investor access through a Nasdaq listing in July 2021, again using the MOLN symbol. The company also pursued infectious-disease applications for its platform. In October 2020, during the COVID-19 pandemic, Novartis acquired a six-percent stake in Molecular Partners at CHF 23 per share as part of a joint venture intended to develop therapeutic drugs against COVID-19. The investment connected Molecular Partners' protein-engineering capabilities with the resources of a major pharmaceutical company and demonstrated the platform's potential use beyond the company's established oncology and ophthalmology focus. Molecular Partners is described in the reference material as a clinical-stage biopharmaceutical business with two DARPin molecules in clinical development and a wider preclinical pipeline. Its operating identity remains centered on research, development, licensing and strategic collaboration rather than the sale of a broad portfolio of approved medicines. The company's long-term prospects depend on the clinical performance and regulatory progress of its candidates, the ability to form productive partnerships and the translation of the DARPin platform into therapies for significant unmet medical needs.
- 2021
Nasdaq listing
[1]The company adds a U.S. Nasdaq listing while continuing to trade under the MOLN ticker.
- 2020
Novartis investment and COVID-19 collaboration
[1]Novartis acquires a six-percent stake in Molecular Partners as part of a joint effort to develop COVID-19 therapeutics.
- 2014
SIX Swiss Exchange listing
[1]Molecular Partners becomes a public company on the SIX Swiss Exchange under ticker MOLN.
- 2012
Additional Allergan ophthalmology agreements
[1]Two further agreements expand cooperation with Allergan on the discovery, development and commercialization of DARPin products for serious ophthalmic diseases.
- 2011
Abicipar is licensed to Allergan
[1]Molecular Partners licenses its lead ophthalmology candidate at the time, abicipar, to Allergan.
- 2004
Molecular Partners is founded
[1]Researchers from the University of Zürich establish Molecular Partners AG to develop DARPin-based medicines and related applications.
Products and positioning
A specialist clinical-stage biotechnology company focused on engineered, modular small-protein therapeutics as an alternative or complement to antibody-based medicines.
Engineered protein therapeutics platform · 2004
DARPin platform
DARPins are genetically engineered binding proteins derived from ankyrin repeat proteins. They are designed to recognize selected biological targets with high affinity and specificity. A mono-DARPin contains one binding domain, while linked multi-DARPins can combine several target-binding or functional domains in one molecule. Molecular Partners applies the platform to investigational medicines and research programs in oncology, immuno-oncology, ophthalmology and infectious diseases.
Ophthalmology investigational therapy · 2011
Abicipar
Abicipar is a DARPin-based ophthalmology candidate that Molecular Partners licensed to Allergan in 2011. It became the company's principal early ophthalmology asset and formed the basis for subsequent cooperation between the two companies on additional DARPin products for serious eye diseases. The reference material identifies the program as an investigational product rather than an established commercial medicine.
Brand decisions
2021
Add a Nasdaq listingOtherBackground
The company sought a U.S. public-market presence in addition to its Swiss listing.
Action taken
Molecular Partners began trading on Nasdaq under ticker MOLN.
Aftermath
The company maintained dual-market visibility in Switzerland and the United States.
2020
Pursue a COVID-19 therapeutic collaboration with NovartisStrategyBackground
The COVID-19 pandemic created demand for new therapeutic approaches and provided an opportunity to apply the DARPin platform to infectious disease.
Action taken
Molecular Partners entered a joint venture with Novartis, which acquired a six-percent stake in the company at CHF 23 per share.
Aftermath
The transaction supported a joint effort to develop therapeutic drugs against COVID-19 and broadened the platform's strategic application.
Novartis share purchase price. CHF 23 per share (October 2020)
2014
List on the SIX Swiss ExchangeOtherBackground
Molecular Partners required public-market access to support the financing and visibility of its clinical-stage biotechnology programs.
Action taken
The company listed its shares on the SIX Swiss Exchange under ticker MOLN.
Aftermath
Molecular Partners became a publicly traded biotechnology company in Switzerland.
2012
Expand the Allergan ophthalmology allianceStrategyBackground
The companies pursued broader use of the DARPin platform in serious ophthalmic diseases.
Action taken
Molecular Partners and Allergan signed two additional agreements covering discovery, development and commercialization of proprietary DARPin products.
Aftermath
The agreements strengthened the company's partnership-led development model in ophthalmology.
2011
License abicipar to AllerganStrategyBackground
Molecular Partners sought to advance its ophthalmology pipeline through cooperation with an established pharmaceutical company.
Action taken
The company licensed its lead ophthalmic candidate at the time, abicipar, to Allergan.
Aftermath
The relationship was expanded through two additional ophthalmology agreements in 2012.
Sources2 sources
Cite this profile: Cite the canonical profile. /brand-wiki/molecular-partners · Editorial policy · How profiles are compiled